• Surgical Science's third-quarter 2026 operating profit rose to SEK 32 million from SEK 27.2 million a year earlier.
• Net sales fell 1% to SEK 260.2 million, with the same decline in local currencies.
• License revenue increased to SEK 76 million from SEK 65.5 million, accounting for 29% of sales.
• Gross margin widened to 68% from 65%.
• For January–September 2026, operating profit climbed to SEK 87.5 million from SEK 28.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Surgical Science Sweden AB published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.